Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 11/20 | 0.51 |
| ▸ | TACR1 | P25103 | 11/20 | 0.51 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | TACR3 | P29371 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200182 | 0.92 | TACR2 (0.52) | TACR2TACR1CCR5TACR3 | |
| SCHEMBL5199737 | 0.91 | TACR2 (0.49) | TACR2TACR1CCR5TACR3 | |
| SCHEMBL5200054 | 0.85 | CCR5 (0.51) | TACR2TACR1CCR5TACR3 | |
| SCHEMBL5199706 | 0.84 | TACR2 (0.52) | TACR2TACR1CCR5TACR3CYP3A4 | |
| SCHEMBL5201160 | 0.84 | CCR5 (0.52) | TACR2TACR1CCR5TACR3 | |
| SCHEMBL5200156 | 0.81 | CCR5 (0.52) | TACR2TACR1CCR5TACR3CYP3A4 | |
| SCHEMBL5201929 | 0.80 | SLC6A2 (0.53) | TACR2TACR1CCR5TACR3CYP2D6 | |
| Hydrochloric Acid SCHEMBL6490210 | 0.80 | CCR5 (0.52) | TACR2TACR1CCR5TACR3CYP3A4 | |
| SCHEMBL5201070 | 0.80 | CCR5 (0.49) | TACR2TACR1CCR5TACR3CYP3A4 | |
| SCHEMBL6664207 | 0.78 | TACR2 (0.43) | TACR2TACR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150970-B1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI AVENTIS (FR) | 2007-08-22 | — | — | EP | disclosed |
| US-6951940-B2 | Piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-10-04 | — | — | US | disclosed |
| US-20040072840-A1 | Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | US | disclosed |
| US-6642233-B1 | Strong affinity and high selectivity for the human NK1 receptors of substance P. | SANOFI-SYNTHELABO (FR) | 2003-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072840-A1 | Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | TACR1, TACR2, KCNJ11 | TACR2 2/4885TACR1 1/4885CCR5 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.